Imunon Q2 2024 GAAP EPS $(0.51) Beats $(0.60) Estimate, Cash, Investments And Accrued Interest Receivable Of $5.3M As Of June 30, 2024 Combined With Net Proceeds Of Approximately $9M From Registered Direct Offering, Capital Resources Are Expected To...
Imunon Q2 2024 GAAP EPS $(0.51) Beats $(0.60) Estimate, Cash, Investments And Accrued Interest Receivable Of $5.3M As Of June 30, 2024 Combined With Net Proceeds Of Approximately $9M From Registered Direct Offering, Capital Resources Are Expected To...
Imunon 2024年第二季度GAAP每股收益爲$(0.51)，超出預期$(0.60)，截至2024年6月30日，現金、投資和應計利息應收款合計爲530萬美元，再加上來自注冊直接發行約900萬美元的淨收益，預計資本資源足以支持運營至2025年第三季度。
Imunon Q2 2024 GAAP EPS $(0.51) Beats $(0.60) Estimate, Cash, Investments And Accrued Interest Receivable Of $5.3M As Of June 30, 2024 Combined With Net Proceeds Of Approximately $9M From Registered Direct Offering, Capital Resources Are Expected To Be Sufficient To Fund Its Operations Into Q3 2025
Imunon 2024年第二季度GAAP每股收益$(0.51)，超過$(0.60)的估計，截止2024年6月30日現金、投資和應收利息合計530萬元，再加上來自注冊直接發行的淨收入約900萬元，資金資源預計足以支持經營活動到2025年第三季度。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。